Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial

4 Nov 2013

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Nanowire Synthesis and Applications
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24190544
DOI: 10.1007/s00262-013-1492-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trialPMID 24190544Read ↗

A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myelomaSemantic proximity Read ↗

Global Manufacturing of CAR T Cell TherapySemantic proximity Read ↗

Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and AccessibilitySemantic proximity Read ↗

Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic functionSemantic proximity Read ↗

Towards a commercial process for the manufacture of genetically modified T cells for therapySemantic proximity Read ↗

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapiesSemantic proximity Read ↗

Optimizing the manufacturing and antitumour response of CAR T therapySemantic proximity Read ↗

Manufacturing Cell and Gene Therapies: Challenges in Clinical TranslationSemantic proximity Read ↗

Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.Semantic proximity Read ↗

Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.Semantic proximity Read ↗

Towards automated manufacturing of clinical scale gene-modified T cellsSemantic proximity Read ↗

A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.